Trump imposes new tariffs. China: stop buying US soya until revoked
Trump announces tariffs from 1 October on medicines at 100% (but in the EU they will remain at 15%), kitchen and bathroom furniture at 50% and trucks at 25%. China is the world's largest buyer of US soya.
3' min read
Key points
3' min read
New barrage of tariffs announced by US President Donald Trump, effective 1 October. Tariffs of 50% will be triggered on kitchen and bathroom furniture and related products. The decision was made, Trump claims, because the US is 'inundated with these products coming in from other countries. It's unfair and we have to protect, for national security reasons, the manufacturing process'.
Pharmaceuticals are also affected: "We will impose 100 per cent tariffs on any branded or patented pharmaceutical product unless a company is building its own pharmaceutical production plant in America," the US president announced on his social Truth, pointing out that "construction will be defined as a start-up and/or construction site. Therefore, there will be no tariffs on these pharmaceuticals if construction has begun'.
Third measure decided by the US president: 25% tariffs on heavy truck imports into the US The decision is dictated by the need to protect 'our manufacturers', he writes in Truth.
EU: 'On medicines 15% limit on tariffs is insurance policy'
"The 15% global tariff cap for EU exports" included in the framework agreement on pharmaceuticals, timber and semiconductors "represents an insurance policy that assures EU economic operators that higher tariffs will not be applied. The EU and the US continue to strive to implement the commitments made in the joint statement, while exploring further areas for exemptions and broader cooperation,' underlines EU Commission spokesman Olof Gill, commenting on Trump's announcement on new medicines in case production does not take place in the US.
100% pharmaceutical tariffs will not apply to the EU and Japan
.Shortly after the EU comment came confirmation from a White House official: the new tariffs on pharmaceutical imports imposed by President Donald Trump will not apply to countries with negotiated agreements with the United States that contain drug provisions, providing the promised relief to economies such as the EU and Japan.

